tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting
PremiumCompany AnnouncementsMolecular Partners Presents Promising MP0533 Trial Data at ASH Meeting
1M ago
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
Premium
The Fly
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
1M ago
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
Premium
The Fly
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
1M ago
Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
PremiumRatingsMolecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
3M ago
Molecular Partners price target lowered to $4 from $4.50 at JPMorgan
Premium
The Fly
Molecular Partners price target lowered to $4 from $4.50 at JPMorgan
4M ago
Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
Premium
Ratings
Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
5M ago
Molecular Partners appoints Martin Steegmaier as chief scientific officer
PremiumThe FlyMolecular Partners appoints Martin Steegmaier as chief scientific officer
5M ago
Molecular Partners’ Promising Oncology Developments and Strategic Focus Earn Buy Rating
Premium
Ratings
Molecular Partners’ Promising Oncology Developments and Strategic Focus Earn Buy Rating
7M ago
Buy Recommendation for Molecular Partners: Promising MP0533 Study Results and Strategic Developments
Premium
Ratings
Buy Recommendation for Molecular Partners: Promising MP0533 Study Results and Strategic Developments
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100